Cachexia is a complex and multifactorial wasting syndrome, associated with several chronic illnesses; including cancer, renal disease, chronic obstructive pulmonary disease, stroke and heart failure. Cachexia results in severe weight loss over time, either through loss of muscle or both muscle and fat. The exact pathophysiology of the syndrome, and its association with chronic illnesses, is not fully understood; although it is known to lead ultimately to catabolic dominance and tissue wasting. More easily understood is the syndrome's high prevalence and debilitating nature, with sufferers experiencing increased frailty, 1 poor quality of life and a greater risk of premature death. 2 For example, one study showed that out of 297 patients with chronic atrial fibrillation, there was 24.6% mortality in 2 years for those with a normal body mass index (BMI) (who were most likely to be classed as cachexic), 15.4% for those classed as overweight and 7.8% for obese individuals. 3 Similar effects are also reported in other work -with an estimated one-year mortality rate of 20-40%. 4 Such a wide approximation of mortality is indicative of the relatively low evidence base surrounding the syndrome, with the majority of research to date focused on cancer. This is further compounded by the lack of a specific definition in cardiac disease, meaning that clinical recognition of the syndrome and research into areas such as its prevalence and clinical implications remain poor. As such, it is challenging for nurses to identify cardiac cachexia and effectively care for those with the syndrome; a situation which is made worse by the current lack of guidelines/interventions to improve quality of and life and outcomes for this patient population. 5 Historical definitions of cachexia focused on the extent of weight loss over periods ranging from 6 to 12 months. Various cut-off values were suggested for this weight loss, such as a BMI of between 18.5 and 23 kg/m 2 or a certain degree of percentage weight loss. For example, in 2006 it was suggested that cardiac cachexia should be defined as weight loss of more than 6% over a period of at least 6 months in a non-oedematous state. 6 However, using these definitions patients with simple starvation would also be classed as cachexic, while those who are naturally thin or have a higher BMI could be misdiagnosed. As such, a more detailed consensus definition was formed in 2008 by Evans et al., 7 that incorporated a number of additional indicators to define the syndrome. According to the definition by Evans et al., 7 cachexia is present when the patient has a weight loss of at least 5% in 12 months or less or BMI less than 20 kg/m 2 , plus three of the following five criteria: (a) decreased muscle strength; (b) fatigue; (c) anorexia; (d) lean tissue depletion; (e) abnormal biochemistry: anaemia (haemoglobin <120 g/L); low serum albumin (<32 g/L) and increased inflammatory markers (C-reactive protein, interleukin-6).
With its comprehensive criteria, the 2008 consensus definition appears to be a useful tool for nurses and other clinicians to identify cachexia. However, an important limitation is that it is not specific to any chronic condition, which is concerning as each varies greatly in their aetiology and progression. For example, considering cardiac cachexia it is important only to use determinations of non-oedematous weight loss, as changes in fluid retention that many patients with heart failure can experience may lead to misdiagnosis. In addition, there is an urgent need for the identification of an effective biomarker, because levels of currently suggested markers such as albumin and C-reactive protein 7 are impacted by common comorbidities in this population other than cachexia. Furthermore, over half of patients with heart failure are anaemic and on some form of iron therapy, meaning haemoglobin may not always be a reliable indicator for cachexia in these individuals. As such, the 2008 consensus definition requires disease-specific refinement for use by cardiac nurses, and should be applied with these limitations in mind.
The ideal biomarker(s) should be specific to cardiac cachexia and not overly influenced by heart failure alone or other comorbidities. More importantly, it should serve as a prognostic indicator -allowing the early identification of the syndrome and improved therapeutic strategies. Biomarkers such as C-terminal agrin fragment 8 and tumour necrosis factor alpha 9 have shown promise in identifying cardiac cachexia, although neither meets the criteria of an ideal biomarker -as neither is specific to cardiac cachexia. Efforts to identify an ideal single marker are challenging, given the polysymptomatic nature of cachexia and its complex pathophysiology, as well as that of heart failure. Furthermore, other factors such as age-related sarcopenia also need to be considered. As such, it has been suggested that a combination of multiple markers should be used, such as products from proteases, to better reflect the multifaceted processes involved in the syndrome. 10 In addition to biomarkers, the other criteria used in the 2008 consensus definition, 7 such as muscle strength and fatigue, can be influenced by confounding factors. Taking muscle strength as an example, obese individuals are known to have greater muscle strength than non-obese persons -although when normalised to body mass they are actually weaker. 11 As such, it is important that the muscle strength of patients with heart failure, who often have a relatively high BMI, is normalised to body mass. 11 Furthermore, muscle strength, fatigue, anorexia and low muscle mass may be influenced by changes in biochemistry, while symptoms such as anorexia and fatigue may be present in individuals without cachexia, such as those with age-related sarcopenia. It is therefore important that nurses consider these confounding factors when identifying patients with cachexia, while further research is needed to enable a consensus definition and improved understanding/management of the syndrome. The first step in this is to recognise that we do not fully understand the impact cachexia has on the daily lives of patients with heart failure and their carers. Such work has been completed in the field of cancer cachexia by Fearon et al. 12 and others, 13 leading to improved and earlier identification of the syndrome. It is now thought that cancer cachexia develops after pre-cachexia -currently defined as weight loss less than 5% of body weight with anorexia and inflammation. Similar work in the field of cardiac cachexia could improve nurses' understanding of the syndrome, allowing for its earlier identification and the development of care which recognises and responds to the needs of this client cohort -targeting improved quality of life, experience and outcomes. It is therefore imperative that work to better elucidate the mechanisms and clinical implications of the syndrome is conducted, which, given its prevalence and debilitating nature, should be a priority in both research and clinical environments.
Implications for practice
• • Cardiac cachexia remains an understudied syndrome, lacking a disease-specific definition, hampering treatment efforts and its identification by healthcare professionals. • • Work to identify effective biomarkers for cardiac cachexia should be a priority, as well as investigations into cut-off values that may allow for its early identification. • • Further research in other areas, such as the syndrome's clinical implications and effect on the daily lives of patients and carers, is also urgently required -to improve understanding of the syndrome and patient outcomes.
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